In over 50 years, however, only two new molecular targeted drugs recognizing B-cell activating factor (BAFF) (belimumab [5]) and IFN-I receptor (anifrolumab [6]) have been approved by FDA as add-on therapies for adult SLE patients. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.